Results 281 to 290 of about 251,408 (329)

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Lancet Oncology, The, 2015
Fred Saad, Cora N Sternberg, Paul De Souza   +2 more
exaly   +2 more sources

Prednisone

Reactions Weekly
  +14 more sources

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Lancet, The, 2007
Thierry Facon, Michel M Attal, Ibrahim Yakoub Agha   +2 more
exaly   +2 more sources

Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial

Annals of the Rheumatic Diseases, 2019
Objectives To compare the efficacy to prevent flares of maintenance versus withdrawal of 5 mg/day prednisone in systemic lupus erythematosus (SLE) patients with clinically quiescent disease.
A. Mathian, M. Pha, J. Haroche, F. Cohen-Aubart, M. Hié, M. Pineton de Chambrun, T. Boutin, M. Miyara, G. Gorochov, H. Yssel, P. Cherin, H. Devilliers, Z. Amoura   +12 more
semanticscholar   +1 more source

Prednisone

Reactions Weekly, 2019
openaire   +2 more sources

Prednisone

Reactions Weekly, 2017
  +7 more sources

Prednisone

Reactions Weekly, 2014
  +5 more sources

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

The Lancet, 2010
J. D. Bono, S. Oudard, M. Ozguroglu, Steinbjørn Hansen, J. Machiels, I. Kocák, G. Gravis, I. Bodrogi, Mary J Mackenzie, L. Shen, M. Roessner, Sunil Gupta, A. O. Sartor   +12 more
semanticscholar   +1 more source